WTR Small-Cap Spotlight

Send us Fan Mail

In this episode of the WTR Small-Cap Spotlight, host Tim Gerdeman and technology analyst James Kisner are joined by Nikolas Bullwinkel, Founder and CEO of Circus SE (Frankfurt: CA1). Bullwinkel previously co-founded quick commerce company Flink, scaling it to a multi-billion Euro valuation before launching Circus to bring full autonomy to the trillion-dollar food service industry. The CA-1 robot replaces entire canteen operations in hospitals, airports, and corporate environments—producing 100 meals per hour with integrated AI, sensors, and the proprietary Circus OS software platform. Bullwinkel highlights the company's razor-blade business model, with each robot adding approximately €100k in annual recurring revenue. Defense applications are accelerating as armed forces seek to modernize logistics infrastructure, with Circus's container-based CA-M deploying in minutes versus hours for traditional field kitchens. With 800,000 meals tested, 40 patents, production partner Celestica ramping capacity, and an order book exceeding 500 units, Bullwinkel characterizes 2026 revenue guidance of €44-55M as conservative and outlines a long-term vision for building a global nutrition intelligence platform.

Send us Fan Mail

Our guest for this Flashcast edition is Shawn Severson, CEO and Co-Founder of Water Tower Research, and Head of Market Commentary and Thematic Research. Shawn breaks down his latest research, “The Cost of Equity Pivot: Why Structure Now Matters More Than Rates,” which challenges the traditional small-cap playbook heading into 2026. 

While falling interest rates have helped fuel a recent rebound in small caps, Shawn explains why the true driver of the innovation economy in 2026 is the cost of equity, not the cost of debt. He outlines the market’s structural shift from “survival financing” to “growth financing,” why markets are now rewarding solvency over dilution, and how investors should position around clean cap tables, funded innovators, and a barbell strategy as the small-cap equity window reopens.

Send us Fan Mail

On this week's episode of the WTR Small-Cap Spotlight, Benjamin Slager, Chief Executive Officer and Chairman of Blue Biofuels (US OTC: BIOF), joined Tim Gerdeman, Vice Chair & Co-Founder and Chief Marketing Officer of Water Tower Research, and Peter Gastreich, Energy and Sustainable Investing Analyst at Water Tower Research. Slager details the company’s innovative CTS technology, which transforms non-food plant material into cellulosic ethanol and sustainable aviation fuel (SAF). Slager highlights the process’s efficiency, low costs, and major carbon reductions compared to corn ethanol. Blue Biofuels is launching its first commercial plant in Florida and partnering with Vertimass LLC for SAF production. With strong market demand, abundant feedstock and cost leadership, Blue Biofuels is positioned for profitability and long-term growth.

Send us Fan Mail

Our guest for this episode is Rick Rosenthal, Director of Business Development at Cboe Global Markets (Cboe: CBOE), where he focuses on helping advisors and wealth managers utilize options-based strategies. He joins Tim Gerdeman, Vice Chair, Co-Founder, and Chief Marketing Officer of Water Tower Research, for a timely discussion on derivatives positioning in the U.S. small-cap market.

Rick explains why Russell 2000 (RUT) options have become a go-to vehicle for gaining or hedging small-cap exposure, highlighting structural advantages versus IWM, rising zero-DTE retail activity, and how investors are using protective puts, spreads, and volatility-harvesting strategies. The conversation also explores macro drivers behind the rotation into small caps, volatility signals from the RVX index, and Cboe’s plan to expand RUT trading to Global Trading Hours in 2026, introducing new access points for both institutional and retail participants.

____

Send us Fan Mail

In this episode of the WTR Small-Cap Spotlight, host Tim Gerdeman and healthcare analyst Robert Sassoon are joined by Dr. Jim Gilligan, President and Chief Science Officer of Entropy Neurodynamics (ASX: ENP), formerly Tryptamine Therapeutics. Dr. Gilligan explains the motivation behind the company’s rebrand and its decision to prioritize three core therapeutic targets: Binge Eating Disorder, Fibromyalgia, and Irritable Bowel Syndrome/abdominal pain. Although Entropy has reported positive Phase 2a results using oral psilocybin across these indications, Dr. Gilligan outlines why the company is shifting its strategy toward developing proprietary IV‑delivered psilocin formulations combined with psychotherapy, beginning with binge eating disorder. The discussion also covers Entropy’s work on real‑time EEG and brain entropy as a potential biomarker, the company’s financing,  regulatory roadmap, and longer‑term expansion opportunities in areas such as PTSD.

Send us Fan Mail

In this special Flashcast episode of the WTR Small-Cap Spotlight podcast, Tim Gerdeman sits down with WTR Healthcare analyst Robert Sassoon to discuss his Initiation of Coverage Report on Anixa Biosciences. Their conversation explores Anixa’s two clinical‑stage programs—one, an innovative CAR‑T cell therapy for terminal ovarian cancer patients, and the other, a breast cancer vaccine designed for both treatment and prevention. They review Phase 1 results, upcoming 2026 milestones, and how Anixa differentiates itself through both its scientific platforms and disciplined financial management.

Send us Fan Mail

In this episode of the WTR Small Cap Spotlight Podcast, LifeVantage President & CEO Steve Fife and Chief Sales Officer Kristen Cunningham join Water Tower Research to discuss the company’s “Breakthrough Era” and strategic priorities for 2026. The conversation covers the successful integration of Love Biome, growing consultant engagement, new science-backed product innovation, and enhanced digital tools designed to drive customer activation and retention. Management also shares insights on upcoming live events and how LifeVantage is positioning itself for sustainable growth in the year ahead. 

Send us Fan Mail

Join Tim Gerdeman, Vice Chair & Co-Founder and Chief Marketing Officer at WTR, and Peter Gastreich, Senior Energy Transition and Sustainability Analyst, as they unpack WTR’s Initiation of Coverage report for Abundia Global Impact Group (NYSE American: AGIG). AGIG's waste-to-value approach converts hard-to-recycle plastics and waste wood into sustainable aviation fuel (SAF), diesel, and more.  AGIG stands out through proven, scalable modular technologies, a prime Houston Shipping Channel location, and strategic partnerships. In terms of sustainability, AGIG both helps to decarbonize transportation and divert waste from landfills. Peter highlights 2026 milestones like site expansion, commercialization steps, and EBITDA scenarios. 

Send us Fan Mail

In this episode, WTR’s Tim Gerdeman is joined by Forum Energy Technologies (NYSE: FET) President & CEO Neal Lux and EVP & CFO Lyle Williams, along with WTR analyst Jeff Robertson, to unpack the company’s FET 2030 strategy and how it builds on FET’s “Beat the Market” playbook.

Send us Fan Mail

In this special Flashcast episode of the WTR Small-Cap podcast, Tim Gerdeman and WTR Healthcare analyst Robert Sassoon break down why more than 90% of biotech companies listed on a U.S. exchange choose NASDAQ over the NYSE.